Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 21.19% is 50% above its 5-year average of 14.16%, around the middle of its 5-year range (10.47%–42.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.60% above its 12-month average of 16.48%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 21.19%.
DEBT TO ASSETS RATIO
21.19%
DEBT TO ASSETS RATIO AVG TTM
16.48%
DEBT TO ASSETS RATIO AVG 3Y
15.06%
DEBT TO ASSETS RATIO AVG 5Y
14.16%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+28.60%
CURRENT VS 3Y AVG
+40.68%
CURRENT VS 5Y AVG
+49.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 834 covered companies
CURRENT VS SECTOR MEDIAN
+23446.10%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$111.84M
Debt to Assets Ratio
21.19%
TTM Avg
16.48%
3Y Avg
15.06%
5Y Avg
14.16%
Market Cap
$112.10M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.21M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.70M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.49M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.89M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.78M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $111.84M | 21.19% | 16.48% | 15.06% | 14.16% |
| BGM Group Ltd. (BGM)vs › | $111.90M | 0.00% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.10M | 0.64% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.21M | 0.09% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.70M | 0.01% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | 0.09% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 0.65% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | 0.09% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.78M | 0.07% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $115.05M | 0.19% | N/A | N/A | N/A |
Debt/Assets
21.2%
Debt/Equity
N/A
Current Ratio
3.36
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 21.19% |
| 2026-03-31 | 18.90% |
| 2025-12-31 | 20.83% |
| 2025-09-30 | 10.99% |
| 2025-06-30 | 10.47% |
| 2025-03-31 | 13.47% |
| 2024-12-31 | 13.08% |
| 2024-09-30 | 12.67% |
| 2024-06-30 | 12.45% |
| 2024-03-31 | 16.85% |
| 2023-12-31 | 15.76% |
| 2023-09-30 | 15.02% |
| 2023-06-30 | 14.12% |
| 2023-03-31 | 13.37% |
| 2022-12-31 | 12.72% |
| 2022-09-30 | 12.25% |
| 2022-06-30 | 12.00% |
| 2022-03-31 | 11.59% |
| 2021-12-31 | 11.22% |
| 2021-09-30 | 42.95% |
| 2021-06-30 | 39.21% |
| 2021-03-31 | 35.84% |
| 2020-12-31 | 32.08% |
| 2020-09-30 | 49.77% |
| 2020-06-30 | 69.67% |
| 2019-12-31 | 74.43% |
